Targeting mutant fibroblast growth factor receptors in cancer

Ornitz, 2001, Fibroblast growth factors, Genome Biol., 2, S3005, 10.1186/gb-2001-2-3-reviews3005 Zhang, 2006, Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family, J. Biol. Chem., 281, 15694, 10.1074/jbc.M601252200 Yan, 1993, Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy, Mol. Cell. Biol., 13, 4513, 10.1128/MCB.13.8.4513 Turner, 2010, Fibroblast growth factor signalling: from development to cancer, Nat. Rev. Cancer, 10, 116, 10.1038/nrc2780 Chesi, 1997, Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3, Nat. Genet., 16, 260, 10.1038/ng0797-260 Richelda, 1997, A novel chromosomal translocation t(4; 14)(p16.3; q32) in multiple myeloma involves the fibroblast growth-factor receptor 3 gene, Blood, 90, 4062, 10.1182/blood.V90.10.4062 Keats, 2003, In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression, Blood, 101, 1520, 10.1182/blood-2002-06-1675 Lauring, 2008, The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity, Blood, 111, 856, 10.1182/blood-2007-05-088674 Intini, 2001, Analysis of FGFR3 gene mutations in multiple myeloma patients with t(4;14), Br. J. Haematol., 114, 362, 10.1046/j.1365-2141.2001.02957.x Rousseau, 1996, Missense FGFR3 mutations create cysteine residues in thanatophoric dwarfism type I (TD1), Hum. Mol. Genet., 5, 509, 10.1093/hmg/5.4.509 Tavormina, 1999, A novel skeletal dysplasia with developmental delay and acanthosis nigricans is caused by a Lys650Met mutation in the fibroblast growth factor receptor 3 gene, Am. J. Hum. Genet., 64, 722, 10.1086/302275 Tavormina, 1995, Thanatophoric dysplasia (types I and II) caused by distinct mutations in fibroblast growth factor receptor 3, Nat. Genet., 9, 321, 10.1038/ng0395-321 d’Avis, 1998, Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I, Cell Growth Differ., 9, 71 Webster, 1996, Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II, Mol. Cell. Biol., 16, 4081, 10.1128/MCB.16.8.4081 Chen, 2007, A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases, Mol. Cell, 27, 717, 10.1016/j.molcel.2007.06.028 Chesi, 2001, Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma, Blood, 97, 729, 10.1182/blood.V97.3.729 Cappellen, 1999, Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas, Nat. Genet., 23, 18, 10.1038/12615 Logie, 2005, Activating mutations of the tyrosine kinase receptor FGFR3 are associated with benign skin tumors in mice and humans, Hum. Mol. Genet., 14, 1153, 10.1093/hmg/ddi127 Tavormina, 1995, Another mutation that results in the substitution of an unpaired cysteine residue in the extracellular domain of FGFR3 in thanatophoric dysplasia type I, Hum. Mol. Genet., 4, 2175, 10.1093/hmg/4.11.2175 van Rhijn, 2004, FGFR3 and P53 characterize alternative genetic pathways in the pathogenesis of urothelial cell carcinoma, Cancer Res., 64, 1911, 10.1158/0008-5472.CAN-03-2421 di Martino, 2009, Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner, Oncogene, 28, 4306, 10.1038/onc.2009.280 Hernandez, 2006, Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas, J. Clin. Oncol., 24, 3664, 10.1200/JCO.2005.05.1771 van Rhijn, 2001, The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate, Cancer Res., 61, 1265 Goriely, 2009, Activating mutations in FGFR3 and HRAS reveal a shared genetic origin for congenital disorders and testicular tumors, Nat. Genet., 41, 1247, 10.1038/ng.470 Dutt, 2008, Drug-sensitive FGFR2 mutations in endometrial carcinoma, Proc. Natl. Acad. Sci. U.S.A., 105, 8713, 10.1073/pnas.0803379105 Pollock, 2007, Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes, Oncogene, 26, 7158, 10.1038/sj.onc.1210529 Wilkie, 2005, Bad bones, absent smell, selfish testes: the pleiotropic consequences of human FGF receptor mutations, Cytokine Growth Factor Rev., 16, 187, 10.1016/j.cytogfr.2005.03.001 Li, 1997, Activation of FGF receptors by mutations in the transmembrane domain, Oncogene, 14, 1397, 10.1038/sj.onc.1200983 Yu, 2000, Loss of fibroblast growth factor receptor 2 ligand-binding specificity in Apert syndrome, Proc. Natl. Acad. Sci. U.S.A., 97, 14536, 10.1073/pnas.97.26.14536 Davies, 2005, Somatic mutations of the protein kinase gene family in human lung cancer, Cancer Res., 65, 7591, 10.1158/0008-5472.CAN-05-1855 Jang, 2001, Mutations in fibroblast growth factor receptor 2 and fibroblast growth factor receptor 3 genes associated with human gastric and colorectal cancers, Cancer Res., 61, 3541 Cornejo-Roldan, 1999, Analysis of the mutational spectrum of the FGFR2 gene in Pfeiffer syndrome, Hum. Genet., 104, 425, 10.1007/s004390050979 Oldridge, 1995, Mutations in the third immunoglobulin domain of the fibroblast growth factor receptor-2 gene in Crouzon syndrome, Hum. Mol. Genet., 4, 1077, 10.1093/hmg/4.6.1077 Tartaglia, 1997, Trp290Cys mutation in exon IIIa of the fibroblast growth factor receptor 2 (FGFR2) gene is associated with Pfeiffer syndrome, Hum. Genet., 99, 602, 10.1007/s004390050413 Robertson, 1998, Activating mutations in the extracellular domain of the fibroblast growth factor receptor 2 function by disruption of the disulfide bond in the third immunoglobulin-like domain, Proc. Natl. Acad. Sci. U.S.A., 95, 4567, 10.1073/pnas.95.8.4567 Andreou, 2006, Early-onset low-grade papillary carcinoma of the bladder associated with Apert syndrome and a germline FGFR2 mutation (Pro253Arg), Am. J. Med. Genet. A, 140, 2245, 10.1002/ajmg.a.31430 Rouzier, 2008, Ovarian dysgerminoma and Apert syndrome, Pediatr. Blood Cancer, 50, 696, 10.1002/pbc.21156 Easton, 2007, Genome-wide association study identifies novel breast cancer susceptibility loci, Nature, 447, 1087, 10.1038/nature05887 Hunter, 2007, A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer, Nat. Genet., 39, 870, 10.1038/ng2075 Meyer, 2008, Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer, PLoS Biol., 6, e108, 10.1371/journal.pbio.0060108 Gartside, 2009, Loss-of-function fibroblast growth factor receptor-2 mutations in melanoma, Mol. Cancer Res., 7, 41, 10.1158/1541-7786.MCR-08-0021 Goradia, 2008, The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report, Int. J. Clin. Exp. Pathol., 1, 448 Ollendorff, 1999, Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation, J. Biol. Chem., 274, 26922, 10.1074/jbc.274.38.26922 Smedley, 1999, ZNF198-FGFR1 transforms Ba/F3 cells to growth factor independence and results in high level tyrosine phosphorylation of STATS 1 and 5, Neoplasia (New York, N.Y.), 1, 349, 10.1038/sj.neo.7900035 Xiao, 2000, ZNF198-FGFR1 transforming activity depends on a novel proline-rich ZNF198 oligomerization domain, Blood, 96, 699, 10.1182/blood.V96.2.699 Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 Rand, 2005, Sequence survey of receptor tyrosine kinases reveals mutations in glioblastomas, Proc. Natl. Acad. Sci. U.S.A., 102, 14344, 10.1073/pnas.0507200102 Bellus, 1995, A recurrent mutation in the tyrosine kinase domain of fibroblast growth factor receptor 3 causes hypochondroplasia, Nat. Genet., 10, 357, 10.1038/ng0795-357 Hart, 2000, Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4, Oncogene, 19, 3309, 10.1038/sj.onc.1203650 Lew, 2009, The precise sequence of FGF receptor autophosphorylation is kinetically driven and is disrupted by oncogenic mutations, Sci. Signal., 2, ra6, 10.1126/scisignal.2000021 Beroukhim, 2010, The landscape of somatic copy-number alteration across human cancers, Nature, 463, 899, 10.1038/nature08822 Weiss, 2010, Frequent and focal FGFR1 Amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer, Sci. Translational Med., 2, 62ra93, 10.1126/scitranslmed.3001451 Turner, 2010, FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer, Cancer Res., 70, 2085, 10.1158/0008-5472.CAN-09-3746 Taylor, 2009, Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models, J. Clin. Invest., 119, 3395 Ruhe, 2007, Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines, Cancer Res., 67, 11368, 10.1158/0008-5472.CAN-07-2703 Roidl, 2010, The FGFR4 Y367C mutant is a dominant oncogene in MDA-MB453 breast cancer cells, Oncogene, 29, 1543, 10.1038/onc.2009.432 Bange, 2002, Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele, Cancer Res., 62, 840 Wang, 2004, The fibroblast growth factor receptor-4 Arg388 allele is associated with prostate cancer initiation and progression, Clin. Cancer Res., 10, 6169, 10.1158/1078-0432.CCR-04-0408 Seitzer, 2010, A single nucleotide change in the mouse genome accelerates breast cancer progression, Cancer Res., 70, 802, 10.1158/0008-5472.CAN-09-3239 Wang, 2008, Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression, Neoplasia (New York, N.Y.), 10, 847, 10.1593/neo.08450 Ding, 2008, Somatic mutations affect key pathways in lung adenocarcinoma, Nature, 455, 1069, 10.1038/nature07423 Kunii, 2008, FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival, Cancer Res., 68, 2340, 10.1158/0008-5472.CAN-07-5229 Trudel, 2004, Inhibition of fibroblast growth factor receptor 3 induces differentiation and apoptosis in t(4;14) myeloma, Blood, 103, 3521, 10.1182/blood-2003-10-3650 Trudel, 2005, CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma, Blood, 105, 2941, 10.1182/blood-2004-10-3913 Xin, 2006, CHIR-258 is efficacious in a newly developed fibroblast growth factor receptor 3-expressing orthotopic multiple myeloma model in mice, Clin. Cancer Res., 12, 4908, 10.1158/1078-0432.CCR-06-0957 Qing, 2009, Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice, J. Clin. Invest., 119, 1216, 10.1172/JCI38017 Bernard-Pierrot, 2006, Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b, Carcinogenesis, 27, 740, 10.1093/carcin/bgi290 Tomlinson, 2007, Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer, Oncogene, 26, 5889, 10.1038/sj.onc.1210399 Miyake, 2010, 1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyr ido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27/Kip1 and G1/G0 arrest, J. Pharmacol. Exp. Ther., 332, 795, 10.1124/jpet.109.162768 Byron, 2008, Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation, Cancer Res., 68, 6902, 10.1158/0008-5472.CAN-08-0770 Shukla, 2007, RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis, Nat. Genet., 39, 1145, 10.1038/ng2096 Gu, 2006, Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia, Blood, 108, 4202, 10.1182/blood-2006-06-026666 Chase, 2007, Activity of TKI258 against primary cells and cell lines with FGFR1 fusion genes associated with the 8p11 myeloproliferative syndrome, Blood, 110, 3729, 10.1182/blood-2007-02-074286 Takeda, 2007, AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor, Clin. Cancer Res., 13, 3051, 10.1158/1078-0432.CCR-06-2743 Bai, 2010, GP369, an FGFR2-IIIb specific antibody, exhibits potent antitumor activity against human cancers driven by activated FGFR2 signaling, Cancer Res., 70, 7630, 10.1158/0008-5472.CAN-10-1489 Turner, 2010, Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets, Oncogene, 29, 2013, 10.1038/onc.2009.489 Lee, 2005, In vivo target modulation and biological activity of CHIR-258, a multitargeted growth factor receptor kinase inhibitor, in colon cancer models, Clin. Cancer Res., 11, 3633, 10.1158/1078-0432.CCR-04-2129 Rosen, 2006, Phase I dose escalation study to determine the safety, pharmacokinetics and pharmacodynamics of BMS-582664, a VEGFR/FGFR inhibitor in patients with advanced/metastatic solid tumors, J. Clin. Oncol., 24, 3051, 10.1200/jco.2006.24.18_suppl.3051 Matsui, 2008, E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition, Int. J. Cancer, 122, 664, 10.1002/ijc.23131 Druker, 2001, Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia, N. Engl. J. Med., 344, 1031, 10.1056/NEJM200104053441401 Joensuu, 2001, Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor, N. Engl. J. Med., 344, 1052, 10.1056/NEJM200104053441404 Lynch, 2004, Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib, N. Engl. J. Med., 350, 2129, 10.1056/NEJMoa040938 Paez, 2004, EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy, Science, 304, 1497, 10.1126/science.1099314 Muenke, 1994, A common mutation in the fibroblast growth factor receptor 1 gene in Pfeiffer syndrome, Nat. Genet., 8, 269, 10.1038/ng1194-269 Wilkie, 1995, Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome, Nat. Genet., 9, 165, 10.1038/ng0295-165 Steinberger, 1998, The mutations in FGFR2-associated craniosynostoses are clustered in five structural elements of immunoglobulin-like domain III of the receptor, Hum. Genet., 102, 145, 10.1007/s004390050668 Johnson, 2000, A novel mutation, Ala315Ser, in FGFR2: a gene-environment interaction leading to craniosynostosis?, Eur. J. Hum. Genet., 8, 571, 10.1038/sj.ejhg.5200499 Przylepa, 1996, Fibroblast growth factor receptor 2 mutations in Beare-Stevenson cutis gyrata syndrome, Nat. Genet., 13, 492, 10.1038/ng0896-492 Kan, 2002, Genomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosis, Am. J. Hum. Genet., 70, 472, 10.1086/338758 Lorenzi, 1997, Ligand-independent activation of fibroblast growth factor receptor-2 by carboxyl terminal alterations, Oncogene, 15, 817, 10.1038/sj.onc.1201242 Bakkar, 2005, Sensitive allele-specific PCR assay able to detect FGFR3 mutations in tumors and urine from patients with urothelial cell carcinoma of the bladder, Clin. Chem., 51, 1555, 10.1373/clinchem.2005.049619 Rousseau, 1994, Mutations in the gene encoding fibroblast growth factor receptor-3 in achondroplasia, Nature, 371, 252, 10.1038/371252a0 van Rhijn, 2002, Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders, Eur. J. Hum. Genet., 10, 819, 10.1038/sj.ejhg.5200883 Hafner, 2006, High frequency of FGFR3 mutations in adenoid seborrheic keratoses, J. Invest. Dermatol., 126, 2404, 10.1038/sj.jid.5700422 Meyers, 1995, Fibroblast growth factor receptor 3 (FGFR3) transmembrane mutation in Crouzon syndrome with acanthosis nigricans, Nat. Genet., 11, 462, 10.1038/ng1295-462 Lindgren, 2006, Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q, Oncogene, 25, 2685, 10.1038/sj.onc.1209249 Bellus, 2000, Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype, Am. J. Hum. Genet., 67, 1411, 10.1086/316892 Platt, 2009, Spectrum of phosphatidylinositol 3-kinase pathway gene alterations in bladder cancer, Clin. Cancer Res., 15, 6008, 10.1158/1078-0432.CCR-09-0898 Heuertz, 2006, Novel FGFR3 mutations creating cysteine residues in the extracellular domain of the receptor cause achondroplasia or severe forms of hypochondroplasia, Eur. J. Hum. Genet., 14, 1240, 10.1038/sj.ejhg.5201700 Sibley, 2001, Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma, Oncogene, 20, 686, 10.1038/sj.onc.1204110 Castro-Feijoo, 2008, Hypochondroplasia and Acanthosis nigricans: a new syndrome due to the p. Lys650Thr mutation in the fibroblast growth factor receptor 3 gene?, Eur. J. Endocrinol., 159, 243, 10.1530/EJE-08-0393 Rousseau, 1995, Stop codon FGFR3 mutations in thanatophoric dwarfism type 1, Nat. Genet., 10, 11, 10.1038/ng0595-11 Huynh, 2008, Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma, Clin. Cancer Res., 14, 6146, 10.1158/1078-0432.CCR-08-0509